Nieves Martínez Lago, Specialist in the Field of Medical Oncology at University Hospital Complex of Santiago de Compostela, shared on X:
“ESMO26 Rapid Oral | Lifileucel
Autologous TIL therapy in refractory UPS/DDLS.
12 enrolled | 10 infused
- ORR: 40% (4/10)
- DCR: 80%
- All 4 PRs ongoing
In-spec product: ORR 50% (4/8).
G4 cytopenias: 10/10.
Promising activity! Phase III SARATOGA underway.”
See more related photos below
